29th Sep 2015 08:48
LONDON (Alliance News) - OptiBiotix Health PLC on Tuesday said it has completed testing and primary analysis on its capsular food supplement, designed to reduce cholesterol levels, and has started pilot manufacturing studies.
The aim of the initial study, conducted with human subjects, was to establish the safety and compliance of the product. OptiBiotix said it could not provide any further information on the studies at this time as the option agreement it signed in June prevents it from being able to do so.
"We are pleased to announce the completion of clinical studies on our capsular food supplement and the sharing of data with our global partner. The product is now undergoing pilot scale manufacturing studies to maximise production yields and volumes," said Stephen O'Hara, OptiBiotix's chief executive.
Shares in OptiBiotix were down 0.1% to 40.94 pence on Tuesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
OptiBiotix Health